Compugen wins on PVRIG European patent opposition pursued by GSK, third party

Compugen (CGEN) announced that the broad claims of Compugen’s Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained. Oppositions were pursued by GSK (GSK) and an anonymous opponent represented by a third party against EP3258951B1. In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen. The opponents can appeal this decision. “We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery.” said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.